• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by Morphic Holding Inc.

    8/26/24 7:39:57 AM ET
    $MORF
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MORF alert in real time by email
    15-12G 1 d227581d1512g.htm 15-12G 15-12G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 15

     

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934.

    Commission File Number: 001-38940

     

     

    MORPHIC HOLDING, INC.

    (Exact name of registrant as specified in its charter)

     

     

    35 Gatehouse Drive, A2

    Waltham, MA 02451

    Telephone: (781) 996-0955

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    Common stock, $0.0001 par value per share

    (Title of each class of securities covered by this Form)

    None

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1)

      ☒

    Rule 12g-4(a)(2)

      ☐

    Rule 12h-3(b)(1)(i)

      ☒

    Rule 12h-3(b)(1)(ii)

      ☐

    Rule 15d-6

      ☐

    Rule 15d-22(b)

      ☐

    Approximate number of holders of record as of the certification or notice date: One holder

    Pursuant to the requirements of the Securities Exchange Act of 1934, Morphic Holding, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

    Date: August 26, 2024     Morphic Holding, Inc.
        By:  

    /s/ Michael C. Thompson

        Name:   Michael C. Thompson
        Title:   President and Treasurer

     

     

     

    Get the next $MORF alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MORF

    DatePrice TargetRatingAnalyst
    12/8/2023$46.00Buy
    Citigroup
    9/25/2023$61.00 → $33.00Hold
    Stifel
    9/25/2023Buy → Neutral
    BTIG Research
    8/9/2023$69.00 → $61.00Buy → Hold
    Stifel
    9/7/2022$44.00Buy
    Stifel
    7/20/2022$45.00Outperform
    SVB Leerink
    3/31/2022$68.00Buy
    Canaccord Genuity
    2/25/2022$82.00 → $76.00Outperform
    RBC Capital
    More analyst ratings

    $MORF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Edwards Martin returned 2,376 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Morphic Holding, Inc. (0001679363) (Issuer)

      8/21/24 4:36:17 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Slattery Joseph P returned 9,066 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Morphic Holding, Inc. (0001679363) (Issuer)

      8/20/24 7:12:13 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Nashat Amir closing all direct ownership in the company (SEC Form 4)

      4 - Morphic Holding, Inc. (0001679363) (Issuer)

      8/20/24 7:11:28 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on Morphic with a new price target

      Citigroup initiated coverage of Morphic with a rating of Buy and set a new price target of $46.00

      12/8/23 7:51:26 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel reiterated coverage on Morphic with a new price target

      Stifel reiterated coverage of Morphic with a rating of Hold and set a new price target of $33.00 from $61.00 previously

      9/25/23 11:48:40 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morphic downgraded by BTIG Research

      BTIG Research downgraded Morphic from Buy to Neutral

      9/25/23 7:17:39 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Omega Funds Closes Oversubscribed $647 Million Fund VIII to Invest in Transformative Life Science Companies

      Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. Since its inception in 2004, Omega Funds has raised $2.5 billion to invest in exceptional entrepreneurs developing

      7/21/25 7:00:00 AM ET
      $BBNX
      $BCAX
      $KMTS
      $MORF
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease

      Broadens Lilly's immunology pipeline with Morphic's oral integrin therapies, including MORF-057 Reinforces the company's strategy of delivering potential first or best-in-class therapies in the field of gastroenterology INDIANAPOLIS, Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ:MORF). Morphic is a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases, including a selective oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD). "We are committed to exploring innovative approaches for i

      8/16/24 8:38:00 AM ET
      $LLY
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease

      Acquisition to expand Lilly's immunology pipeline with oral integrin therapies INDIANAPOLIS and WALTHAM, Mass., July 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Morphic Holding, Inc. (NASDAQ:MORF) today announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases. Morphic's lead program is a selective oral small molecule inhibitor of α4β7 integrin for the treatment of inflammatory bowel disease (IBD) that has the potential to improve outcomes and expand treatment options for patients. This molecule (known as MORF-057) is being evaluated in two Phase 2 studies in ulcera

      7/8/24 6:45:00 AM ET
      $LLY
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    Financials

    Live finance-specific insights

    See more
    • Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease

      Broadens Lilly's immunology pipeline with Morphic's oral integrin therapies, including MORF-057 Reinforces the company's strategy of delivering potential first or best-in-class therapies in the field of gastroenterology INDIANAPOLIS, Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ:MORF). Morphic is a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases, including a selective oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD). "We are committed to exploring innovative approaches for i

      8/16/24 8:38:00 AM ET
      $LLY
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023

      -Presented positive EMERALD-1 Phase 2a data for MORF-057 in patients with moderate to severe ulcerative colitis at UEG Week 2023- -Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Ended third quarter with $725.1 million in cash, cash equivalents, and marketable securities providing runway into the second half of 2027- WALTHAM, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the third quarter 2023. "Morphic presented a compre

      11/3/23 7:00:00 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set

      WALTHAM, Mass., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced it will host a webcast and conference call to discuss the complete results from the open-label EMERALD-1 Phase 2a study of MORF-057 in adults with moderate to severe ulcerative colitis. The positive topline results from EMERALD-1 were reported in April of this year and the full data set will be presented at the upcoming UEG Week 2023. The webcast and call will be held at 7:45 AM Eastern Time on October 12, 2023. A live webcast of the call will be available via

      10/9/23 8:00:00 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Edwards Martin bought $48,803 worth of shares (2,376 units at $20.54) (SEC Form 4)

      4 - Morphic Holding, Inc. (0001679363) (Issuer)

      11/15/23 7:00:10 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Slattery Joseph P bought $49,436 worth of shares (2,400 units at $20.60), increasing direct ownership by 36% to 9,066 units (SEC Form 4)

      4 - Morphic Holding, Inc. (0001679363) (Issuer)

      11/14/23 7:04:11 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    Leadership Updates

    Live Leadership Updates

    See more
    • Morphic Appoints Dr. Simon Cooper as Chief Medical Officer

      WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Simon Cooper, M.B.B.S., has joined the Company as Chief Medical Officer. Dr. Cooper is an accomplished leader in drug development with appreciable success and a proven history across all phases of clinical development and in a wide variety of therapeutic areas, particularly autoimmune, inflammatory, cardiovascular, and pulmonary diseases. Dr. Cooper most recently served as Chief Medical Officer of Keros Therapeutics. "Simon brings clinical development expe

      3/19/24 8:00:00 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morphic Announces Corporate Highlights and Financial Results for the Full Year 2022

      -Initiated and completed enrollment for EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis; topline data expected 2Q23- -Launched EMERALD-2 phase 2b global randomized trial of MORF-057 in ulcerative colitis- -Ended 2022 with $348 million in cash and equivalents; ~$100 million from February private placement extends cash runway into second half of 2026 WALTHAM, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the full year 2022. 2022 and Recent Corporate H

      2/23/23 8:00:00 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morphic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs

      WALTHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Joanne Gibbons has been named Senior Vice President of Regulatory Affairs. Ms. Gibbons was previously Vice President and Head of Regulatory Affairs at Codiak Biosciences. "Joanne arrives at Morphic at a promising time. We are advancing clinical and pre-clinical integrin inhibitors generated by the MInT Platform and Joanne brings successful leadership experience across the full spectrum of regulatory affairs from preclinical activities through drug commer

      5/18/22 7:30:00 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    SEC Filings

    See more
    • SEC Form 15-12G filed by Morphic Holding Inc.

      15-12G - Morphic Holding, Inc. (0001679363) (Filer)

      8/26/24 7:39:57 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Morphic Holding Inc.

      S-8 POS - Morphic Holding, Inc. (0001679363) (Filer)

      8/16/24 4:27:56 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Morphic Holding Inc.

      S-8 POS - Morphic Holding, Inc. (0001679363) (Filer)

      8/16/24 4:25:26 PM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MORF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Morphic Holding Inc.

      SC 13G/A - Morphic Holding, Inc. (0001679363) (Subject)

      8/12/24 9:40:06 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Morphic Holding Inc.

      SC 13G/A - Morphic Holding, Inc. (0001679363) (Subject)

      8/7/24 7:47:40 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Morphic Holding Inc.

      SC 13G/A - Morphic Holding, Inc. (0001679363) (Subject)

      7/8/24 10:07:20 AM ET
      $MORF
      Biotechnology: Pharmaceutical Preparations
      Health Care